Block self serving small business management from accepting buyouts from larger companies without shareholder approval.

Astellas Pharma, a Japanese company, is currently attempting to acquire Ocata Therapeutics, a US company, via tender offer. Ocata CSO, Dr. Robert Lanza, patented a way to culture embryonic stem cells without harming the embryo. Ocata held a trial in which the world's leading cause of blindness was reversed/halted rather quickly using these cells. Even after 4 years, there is major improvement to their vision & no adverse effects. These cells have also shown promise in potentially curing a plethora of other afflictions, e.g., MS, Crohn's disease, and Sepsis. Paul Wotton took over as CEO in 2014. As was recently discovered, he almost immediately began discussions with Astellas without shareholder knowledge and assured he leaves with a hefty payday. The US can't lose this technology to Japan.